<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994834</url>
  </required_header>
  <id_info>
    <org_study_id>HND-IN-037</org_study_id>
    <nct_id>NCT04994834</nct_id>
  </id_info>
  <brief_title>Characterization of the Gastrointestinal Microbiota in Term Newborn Infants After 4 Weeks Supplementation of Probiotics</brief_title>
  <official_title>Characterization of the Gastrointestinal Microbiota in Term Newborn Infants After 4 Weeks Supplementation of Probiotics - an Open Label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chr Hansen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A mono center, open label, pilot study in term newborn infants. The study will investigate&#xD;
      the effect of supplementation with probiotics on the presence of total Bifidobacterium in the&#xD;
      infant feces.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The four weeks intervention starts within 24 hours after birth of the study subject and the&#xD;
      investigational product will be given for 28 days, followed by a two weeks follow-up period&#xD;
      without any intake of the investigational product.&#xD;
&#xD;
      During the entire study period, five visits are scheduled. Visit 2 to Visit 5 are home visits&#xD;
      by the study midwife. From Visit 2 and throughout the study period (Visit 2 to Visit 5) the&#xD;
      parents will be asked to complete a diary daily.&#xD;
&#xD;
      Infant stool samples will be collected on multiple occasions during the study, as well as&#xD;
      maternal breast milk samples, stool and urine samples and samples from vagina. In addition,&#xD;
      sample from placenta, umbilical cord, umbilical cord blood and amnion fluid will be&#xD;
      collected. Mothers will be asked to complete electronic questionnaires daily during the&#xD;
      course of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of the investigational product in the infant feces</measure>
    <time_frame>28 days after birth</time_frame>
    <description>Presence of the investigational product in infant fecal samples after 4 weeks of supplementation (Visit 4) using PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fecal Bifidobacterium in infant fecal samples</measure>
    <time_frame>Baseline, Day14, Day 28</time_frame>
    <description>Total fecal Bifidobacterium in infant fecal samples after 4 weeks supplementation Quantification of total Bifidobacterium will be determined by PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the infant intestinal microbiota after 4 weeks supplementation</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>Characterization of the infant intestinal microbiota after 4 weeks supplementation of the investigational product using sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (Safety)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Frequency and severity of adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mothers fecal microbiota</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of mother's microbiota from fecal samples will be assessed using sequencing to examine the microbiota for similarities with the infant</description>
  </other_outcome>
  <other_outcome>
    <measure>Infant Gastrointestinal Problems</measure>
    <time_frame>42 days</time_frame>
    <description>Infant Gastrointestinal Problems will be measured using ROME IV Diagnostic Questionnaires for Pediatric Functional Gastrointestinal Disorders for Neonates and Toddlers: Parent-Report Form for Neonates Section A - Infant Gastrointestinal Problems</description>
  </other_outcome>
  <other_outcome>
    <measure>Stool frequency and consistency</measure>
    <time_frame>42 days</time_frame>
    <description>Infant stool frequency and consistency will be measured using Amsterdam Stool Chart.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reflux</measure>
    <time_frame>42 days</time_frame>
    <description>Reflux will be measured using Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R)</description>
  </other_outcome>
  <other_outcome>
    <measure>Breastmilk microbiome</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>Microbiome of the breastmilk to be assessed using sequencing to explore a potential microbiota of the breastmilk</description>
  </other_outcome>
  <other_outcome>
    <measure>Mothers vaginal microbiota</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of mother's vaginal microbiota will be assessed using sequencing to examine the microbiota for similarities with the infant</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Once a day daily intake of probiotics for at least 28 consecutive starting within 24 hours after birth</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Infants to be enrolled at birth.&#xD;
&#xD;
        Inclusion Criteria for Infants (study subjects)&#xD;
&#xD;
          -  Gestational age at birth ≥ 37±0 ≤ weeks 42±0 weeks&#xD;
&#xD;
          -  Birthweight more than 2500 g&#xD;
&#xD;
          -  No exposure to oral or intravenous antibiotics&#xD;
&#xD;
          -  No complications that need medical interventions (e.g. respiratory distress symptoms&#xD;
             or infections)&#xD;
&#xD;
          -  Both legal guardians provided voluntary written informed consent on behalf of the&#xD;
             infant&#xD;
&#xD;
        Pregnant women:&#xD;
&#xD;
          -  Women age above 18 years at informed consent&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Uncomplicated pregnancy&#xD;
&#xD;
          -  No use of medication&#xD;
&#xD;
          -  Aim to give birth vaginally and breastfeed&#xD;
&#xD;
          -  No use of probiotics during the last month before estimated birth and until six weeks&#xD;
             postpartum&#xD;
&#xD;
          -  Provided voluntary written informed consent&#xD;
&#xD;
        Exclusion criteria for Infants (study subjects)&#xD;
&#xD;
        • Admission to the neonatal intensive care unit (NICU)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Henning Pedersen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gynecology and Obstetrics, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Høtoft, Midwife</last_name>
    <phone>+4523486730</phone>
    <email>diahoe@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Henning Pedersen, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynaecology and Obstetrics</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Høtoft, Midwife</last_name>
      <phone>+4523486730</phone>
      <email>diahoe@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Diana Høtoft, Midwife</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To share IPD not decided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

